a personalised cancer vaccine using genetic material cloned patients tumour cells begin clinical trial month the trial approved yesterday medicines control agency it latest example gene therapy one fastest growing medical research fields first vaccine tailormade individual scientists cancer research campaign medical research council working mrc protein engineering centre cambridge devised approach it aimed initially bcell lymphoma relatively rare cancer lymph nodes affecting 2500 people year britain it could later extended common cancers bcell lymphoma especially suitable treatment personal vaccine cancer cells marker proteins targets attack bodys immune system vary distinctly individuals the experimental procedure involves removing marker gene patients lymphoma cells splicing bacteria make millions copies gene multiply culture the genes cut bacteria special enzymes purified injected patient the idea backed promising results animal experiments reintroduced genes make relatively large amounts cancer marker this stimulate patients immune system attack cancer cells effectively ten patients addenbrookes hospital cambridge royal bournemouth hospital take part initial trial if respond well trial extended dr david secher drug development director cancer research campaign said its important stress currently vaccine appropriate patients particular type bcell lymphoma however researchers hope work may lead vaccines developed common cancers the campaign testing nonpersonalised vaccine bowel cancer nottingham university it also designed prime immune system attack cancer cells the personalisation procedure far elaborate potential commercial use it would automated simplified designer vaccines ever become routine treatment